Literature DB >> 35198201

Usefulness of position emission tomography/computed tomography in a case of sarcoidosis with multiorgan involvement.

Norihiko Amano1, Soshi Takahashi1, Saori Hatachi1, Shunichi Kumagai1.   

Abstract

Sarcoidosis, a systemic inflammatory disease of unknown etiology, can affect any site in the body. A bone lesion was unexpectedly detected by fluorodeoxyglucose position emission tomography/computed tomography (FDG PET/CT) in a patient with multiorgan sarcoidosis. FDG PET/CT should be considered for the detection of clinically silent lesions of sarcoidosis.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FDG PET/CT; bone sarcoidosis; massive splenomegaly; multiorgan; sarcoidosis

Year:  2022        PMID: 35198201      PMCID: PMC8841028          DOI: 10.1002/ccr3.5358

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


CASE PRESENTATION

A 48‐year‐old female patient noticed a subcutaneous nodule. She presented with remittent fever, fatigue, weight loss, and abdominal pain. Laboratory tests showed elevated levels of lysozyme, soluble interleukin‐2 receptor, and angiotensin‐converting enzyme. Computed tomography (CT) revealed pulmonary reticular opacities, hepatomegaly, and massive splenomegaly. Fluorodeoxyglucose position emission tomography (FDG PET)/CT showed FDG uptake not only in the liver, spleen, and systemic lymph nodes but also in the humerus, scapula, the 4–7th thoracic vertebrae, pelvis, and femur (Figures 1 and 2). Histological samples from the skin, liver, and bone marrow biopsies exhibited noncaseating granulomas with epithelioid cells, which were diagnosed as multiorgan sarcoidosis.
FIGURE 1

Coronal FDG PET (A) and sagittal FDG PET (B) show FDG uptake in the liver, spleen, systemic lymph nodes, humerus, scapula, the 4–7th thoracic vertebrae, pelvis, and femur

FIGURE 2

(A) Sagittal FDG PET/CT shows FDG uptake in the 4–7th thoracic vertebrae (arrow). (B) Axial FDG PET/CT shows FDG uptake in the scapula (arrow) and humerus (arrowhead). (C) Coronal FDG PET/CT shows FDG uptake in the pelvis (arrows) and femur (arrowheads)

Coronal FDG PET (A) and sagittal FDG PET (B) show FDG uptake in the liver, spleen, systemic lymph nodes, humerus, scapula, the 4–7th thoracic vertebrae, pelvis, and femur (A) Sagittal FDG PET/CT shows FDG uptake in the 4–7th thoracic vertebrae (arrow). (B) Axial FDG PET/CT shows FDG uptake in the scapula (arrow) and humerus (arrowhead). (C) Coronal FDG PET/CT shows FDG uptake in the pelvis (arrows) and femur (arrowheads) Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the formation of noncaseating granulomas in the affected organs. Although FDG PET/CT is not included in the standard workup for sarcoidosis, its usefulness in the diagnosis of this condition and its subsequent management have been proposed.  Moreover, FDG PET/CT has been reported to be especially useful in detecting bone lesions because it is difficult to detect bone sarcoidosis involvement using conventional radiography. Sarcoidosis can affect any site in the body while being asymptomatic. Therefore, FDG PET/CT should be considered for the detection of affected lesions of sarcoidosis.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTION

ST and TA contributed to the writing of this case and to the acquisition of the respective images. SH and KS reviewed and edited the manuscript.

ETHICAL APPROVAL

None.

CONSENT

Written informed consent was obtained from the patient for the publication of this case report and accompanying images.
  2 in total

Review 1.  PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations.

Authors:  Gensuke Akaike; Malak Itani; Hardik Shah; Jitesh Ahuja; Burcak Yilmaz Gunes; Richard Assaker; Fatemeh Behnia
Journal:  Radiographics       Date:  2018-08-17       Impact factor: 5.333

2.  18F-FDG PET/CT in bone sarcoidosis: an observational study.

Authors:  Lucie Demaria; Raphael Borie; Khadija Benali; Eve Piekarski; Julia Goossens; Elisabeth Palazzo; Marine Forien; Philippe Dieudé; Bruno Crestani; Sébastien Ottaviani
Journal:  Clin Rheumatol       Date:  2020-03-20       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.